BIO-TECHNE Corp TECH revenue by segment, product and geography
In its fiscal year ending 2026-06-30, BIO-TECHNE Corp reported revenue across 5 products and services; the largest, Product And Services, was $1.19B (-0.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product And Services$1.19Bshare n/a-0.5% yoy
- Consumables$985Mshare n/a+1.3% yoy
- Instruments$111Mshare n/a-1.3% yoy
- Service$94.3Mshare n/a-15.5% yoy
- Royalty$25Mshare n/a+5.5% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$635M52.3%-7.0% yoy
- EMEA Excluding UK$294M24.2%+10.5% yoy
- China$104M8.6%+3.6% yoy
- APAC Excluding Greater China$85.8M7.1%+11.1% yoy
- United Kingdom$56.3M4.6%+2.7% yoy
- Rest of world$39.3M3.2%+4.6% yoy
Members sum to the consolidated $1.22B for this period.
- Product And Services$306Mshare n/a-1.5% yoy
- Consumables$257Mshare n/a-0.2% yoy
- Instruments$27.7Mshare n/a+5.9% yoy
- Service$21.4Mshare n/a-21.3% yoy
- Royalty$4.97Mshare n/a-1.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.